Biohaven (BHVN) Total Non-Current Liabilities (2021 - 2026)
Biohaven (BHVN) reported Total Non-Current Liabilities of $332.3 million for Q1 2026, up 199.06% on a YoY basis from $111.1 million in Q1 2025, and down 15.82% sequentially from $394.8 million in Q4 2025.
Biohaven (BHVN) Total Non-Current Liabilities (2021 - 2026) Analysis & Trends
Biohaven (BHVN) has 6 years of Total Non-Current Liabilities data on file, last reported at $332.3 million in Q1 2026.
- For the quarter ending Q1 2026, Total Non-Current Liabilities rose 199.06% year-over-year to $332.3 million; the trailing twelve-month figure through Mar 2026 stood at $332.3 million (up 199.06% YoY), and the FY2025 full-year result was $394.8 million, up 111.11% from the prior year.
- Total Non-Current Liabilities slipped to $332.3 million in Q1 2026, from $394.8 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $394.8 million in Q4 2025 to a low of $28.4 million in Q3 2022.
- A 5-year average of $161.6 million and a median of $143.8 million in 2023 frame the typical range for Total Non-Current Liabilities.
- Peak annual rise in Total Non-Current Liabilities reached 218.14% in 2023, while the deepest fall reached 31.19% in 2023.
- Tracing BHVN's Total Non-Current Liabilities over 5 years: stood at $120.6 million in 2022, then slumped by 31.19% to $83.0 million in 2023, then jumped by 125.33% to $187.0 million in 2024, then jumped by 111.11% to $394.8 million in 2025, then declined by 15.82% to $332.3 million in 2026.
- Business Quant data shows BHVN's Total Non-Current Liabilities at $332.3 million in Q1 2026, $394.8 million in Q4 2025, and $158.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Biohaven | 2.16 Bn | 1.81 Bn | - | 332.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 332.35 Mn |
| Dec 31, 2025 | 394.79 Mn |
| Sep 30, 2025 | 158.01 Mn |
| Jun 30, 2025 | 158.76 Mn |
| Mar 31, 2025 | 111.13 Mn |
| Dec 31, 2024 | 187.01 Mn |
| Sep 30, 2024 | 189.93 Mn |
| Jun 30, 2024 | 194.58 Mn |
| Mar 31, 2024 | 113.67 Mn |
| Dec 31, 2023 | 82.99 Mn |
| Sep 30, 2023 | 90.46 Mn |
| Jun 30, 2023 | 116.96 Mn |
| Mar 31, 2023 | 143.77 Mn |
| Dec 31, 2022 | 120.60 Mn |
| Sep 30, 2022 | 28.44 Mn |
| Dec 31, 2021 | 44.73 Mn |